ATE381945T1 - Verfahren zur solubilisierung von peptid- mischungen - Google Patents

Verfahren zur solubilisierung von peptid- mischungen

Info

Publication number
ATE381945T1
ATE381945T1 AT05727232T AT05727232T ATE381945T1 AT E381945 T1 ATE381945 T1 AT E381945T1 AT 05727232 T AT05727232 T AT 05727232T AT 05727232 T AT05727232 T AT 05727232T AT E381945 T1 ATE381945 T1 AT E381945T1
Authority
AT
Austria
Prior art keywords
acid
peptide mixture
peptide mixtures
aqueous solution
solubilizing
Prior art date
Application number
AT05727232T
Other languages
English (en)
Inventor
Wolfgang Zauner
Constantia Kritsch
Christa Heinrich-Cseh
Agnes Berger
Original Assignee
Intercell Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Ag filed Critical Intercell Ag
Application granted granted Critical
Publication of ATE381945T1 publication Critical patent/ATE381945T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT05727232T 2004-03-12 2005-03-11 Verfahren zur solubilisierung von peptid- mischungen ATE381945T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04450061 2004-03-12

Publications (1)

Publication Number Publication Date
ATE381945T1 true ATE381945T1 (de) 2008-01-15

Family

ID=35064441

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05727232T ATE381945T1 (de) 2004-03-12 2005-03-11 Verfahren zur solubilisierung von peptid- mischungen

Country Status (6)

Country Link
US (1) US20080145383A1 (de)
EP (2) EP1722819B1 (de)
AT (1) ATE381945T1 (de)
DE (1) DE602005004014T2 (de)
ES (1) ES2297688T3 (de)
WO (1) WO2005094891A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US20100278822A1 (en) * 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
AR077384A1 (es) * 2010-07-05 2011-08-24 Eriochem Sa Una formulacion farmaceutica inyectable de melfalano.
TWI603739B (zh) 2010-11-11 2017-11-01 艾伯維生物技術有限責任公司 具有增進高濃度之抗－ＴＮＦα抗體之液體調配物
GB201022147D0 (en) 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
WO2012122535A2 (en) 2011-03-10 2012-09-13 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
JP6117811B2 (ja) 2011-10-31 2017-04-19 ゼリス ファーマシューティカルズ インコーポレイテッド 糖尿病を処置するための製剤
MX344635B (es) 2012-03-23 2017-01-04 Amicrobe Inc Composiciones y usos de materiales antimicrobianos con propiedades compatibles con el tejido.
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
KR102428675B1 (ko) 2014-08-06 2022-08-02 엑스에리스 파머수티클스, 인크. 페이스트의 피내 및／또는 피하 주사를 위한 주사기, 키트, 및 방법
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
CN110740744A (zh) * 2017-04-06 2020-01-31 艾麦克罗比公司 性能和安全性增强的局部施用的抗微生物剂的组合物和应用
CN117085022A (zh) 2017-06-02 2023-11-21 Xeris药物公司 抗沉淀的小分子药物制剂

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05112464A (ja) * 1991-04-09 1993-05-07 Sanwa Kagaku Kenkyusho Co Ltd 安定化された ［Ｌｅｕ１３−ｍｏｔｉｌｉｎ−Ｈｓｅ 医薬組成物
NZ243090A (en) * 1991-06-18 1993-11-25 Lilly Co Eli Method of identifying active peptides and synthesis of peptide mixtures with a known amino acid in the last coupled position
DE4305225A1 (de) 1993-02-19 1994-08-25 Asta Medica Ag Neues Herstellverfahren für Cetrorelix Lyophilisat
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
EP0788370A4 (de) * 1993-07-09 1998-07-08 Smithkline Beecham Corp Zyklische, teilzufallige peptidbibliotheken
DE4402756A1 (de) * 1994-01-31 1995-08-03 Boehringer Mannheim Gmbh Spezifische Bindungssubstanzen für Antikörper und deren Verwendung für Immunoassays oder Vakzine
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
EP0998942A4 (de) * 1997-01-20 2006-08-16 Japan Energy Corp Verfahren zur stabilisierung von peptiden und gefriergetrochnete medizinische zusammensetzungen mit diesen
DE19803453A1 (de) 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
US20020019061A1 (en) * 1999-08-31 2002-02-14 Hung-Sen Lai Purification and analysis of cyclic peptide libraries, and compositions thereof
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
JP4516711B2 (ja) * 1999-12-28 2010-08-04 中外製薬株式会社 安定な抗体組成物及び注射製剤
DE10024451A1 (de) * 2000-05-18 2001-11-29 Asta Medica Ag Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung
AU2001289813B2 (en) 2000-08-17 2005-07-28 Intercell Ag A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
GB0218821D0 (en) * 2002-08-13 2002-09-18 Glaxosmithkline Biolog Sa Novel compositions
EP1537418A2 (de) * 2002-09-13 2005-06-08 Intercell AG Verfahren zur isolierung von hepatitis c virus peptiden
CA2530062A1 (en) * 2003-07-11 2005-01-20 Intercell Ag Hcv vaccines

Also Published As

Publication number Publication date
EP1987843A3 (de) 2011-10-26
ES2297688T3 (es) 2008-05-01
WO2005094891A2 (en) 2005-10-13
WO2005094891A3 (en) 2006-03-16
DE602005004014D1 (de) 2008-02-07
EP1722819A2 (de) 2006-11-22
US20080145383A1 (en) 2008-06-19
EP1722819B1 (de) 2007-12-26
DE602005004014T2 (de) 2008-12-11
EP1987843A2 (de) 2008-11-05

Similar Documents

Publication Publication Date Title
DE602005004014D1 (de) Verfahren zur solubilisierung von peptid-mischungen
Swinnen et al. Facile, Fmoc-compatible solid-phase synthesis of peptide C-terminal thioesters
Frohman et al. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma.
Botti et al. Native chemical ligation through in situ O to S acyl shift
ATE551423T1 (de) Sequenzen von hepatitis c virus-genotypen sowie ihre verwendungen als therapeutika und diagnostika
ATE478944T1 (de) Zytokin ligand zur behandlung von asthma und atemwegsüberreaktivität
Spatola et al. Rediscovering an endothelin antagonist (BQ-123): A self-deconvoluting cyclic pentapeptide library
DE60041119D1 (de) Verfahren zur präsentation von (poly)peptiden/proteinen auf bakteriophagenpartikeln via disulfidbindungen
PT948541E (pt) Analogos da pthrp
DK0929574T3 (da) Modulatorer af beta-amyloidpeptidaggregering, som omfatter D-aminosyrer
ATE353911T1 (de) Verfahren zur rekombinanten herstellung von antifusogenikpeptide
ATE392430T1 (de) Verfahren zur herstellung von dipeptiden
ATE429920T1 (de) Pharmazeutische zusammensetzung und verfahren zur behandlung von hypogonadismus
WO2002002627A3 (en) Interferon-like protein zcyto21
WO2006090385A3 (en) Protease inhibitors and method of screening thereof
DE69723485D1 (de) Verfahren zur Identifizierung von Wirkstoffen gegen HCV durch Verwendung von Strukturkoordinaten der Hepatitis-C-Virus-Protease
ATE260972T1 (de) Verfahren zur aktivierung von denaturiertem protein
ATE358139T1 (de) Verfahren zur herstelllung von gonadotropin- zusammensetzungen
NO991198D0 (no) FremgangsmÕte ved fremstilling av et plasmaproteinholdig legemiddel
DE60024821D1 (de) Verfahren zur reinigung von aldehydverunreinigungen
WO2004014936A3 (fr) Melange de peptides issus des proteines c et ns3 du virus de l'hepatite c et leurs applications.
ATE516306T1 (de) Verbessertes verfahren zur reinigung von tfpi und tfpi-analogen
ATE436041T1 (de) Unter biokompatiblen bedingungen verarbeitbare fotoresists zur erzeugung von biomolekül-mustern
KR980002263A (ko) C형 간염 바이러스의 프로테아제의 활성을 측정할 수 있는 c형 간염 대체 바이러스, 그 재조합 유전자 및 그 용도
Abiko et al. Chemical syntheses of CART (human, 55-102) analogues and their anorectic effect on food intake in rats induced by neuropeptide Y

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1722819

Country of ref document: EP